Idelalisib, Sold Under the Brand Name Zydelig: A Medication for the Treatment of Chronic Lymphocytic Leukaemia, Follicular Lymphoma – Global Drug Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com

Idelalisib, Sold Under the Brand Name Zydelig: A Medication for the Treatment of Chronic Lymphocytic Leukaemia, Follicular Lymphoma – Global Drug Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com




Idelalisib, Sold Under the Brand Name Zydelig: A Medication for the Treatment of Chronic Lymphocytic Leukaemia, Follicular Lymphoma – Global Drug Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Zydelig – Drug Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

The Zydelig- Drug Insight and Market Forecast – 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Zydelig in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product.

The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary

Idelalisib, sold under the brand name Zydelig is a medication for the treatment of Chronic lymphocytic leukaemia, Follicular lymphoma. Zydelig is indicated for the treatment of patients with relapsed follicular B-cell nonHodgkin lymphoma (FL) who have received at least two prior systemic therapies. Idelalisib is an inhibitor of PI3K kinase, which is expressed in normal and malignant Bcells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells.

Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of chemotaxis and adhesion, and reduced cell viability.

In July 2014, the FDA granted accelerated approval to idelalisib (Zydelig tablets; Gilead Sciences, Inc.) for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma or relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Zydelig.
  • The report contains historical and forecasted sales for Zydelig till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Zydelig.

Zydelig Analytical Perspective

In-depth Zydelig Market Assessment

This report provides a detailed market assessment of Zydelig in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Zydelig Clinical Assessment

The report provides the clinical trials information of Zydelig covering trial interventions, trial conditions, trial status, start and completion dates.

Key Questions Answered

  • What is the prescribed dosage and strengths of Zydelig are available in the market?
  • What are the common adverse reactions or side effects of Zydelig?
  • What is the product type, route of administration and mechanism of action of Zydelig?
  • What are the chemical specifications of Zydelig?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Zydelig, and what is its future?
  • What are the marketed details of Zydelig in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Zydelig and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Zydelig?
  • In which countries Zydelig got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Zydelig?
  • How the safety and efficacy results determined the approval of Zydelig?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Zydelig development?
  • What are the key designations that have been granted to Zydelig?
  • What is the historical and forecasted market scenario of Zydelig?
  • How is the market trend of Zydelig is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Zydelig?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

 

Key Topics Covered:

 

1. Product Overview

1.1. Indication

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4.1 Dosage Forms and Strengths

1.4. Route of Synthesis

1.5. Pharmacology

1.4.2 Pharmacodynamics

1.4.3 Pharmacokinetics

1.6. Adverse Reactions

1.7. Product Snapshot

1.8. Development Milestones of Zydelig

1.9. Marketed Details

1.4.4 United States

1.4.5 Europe

1.4.6 Japan

1.10. Patent Details

 

2. SWOT Analysis

2.1. Analyst Views

 

3. Regulatory Milestones

3.1. Approvals

3.2. Research and Development

3.3. Clinical Trials Information

3.4. Safety and Efficacy

3.5. Product Developmental Activities

 

4. Market Assessment

4.1. 7MM Market Analysis

4.2. United States

4.3. Europe

4.4. Japan

4.5. Key Findings

 

5. Market Competitors

 

6. Emerging Therapies

 

7. Appendix

 

For more information about this report visit https://www.researchandmarkets.com/r/eqrt1t.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900